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Abstract
Objective To examine the effectiveness of post-diagnosis dementia
treatment and coordination of care by memory clinics compared with
general practitioners.
Design Multicentre randomised controlled trial.
Setting Nine memory clinics and 159 general practitioners in the
Netherlands.
Participants 175 patients with a new diagnosis of mild to moderate
dementia living in the community and their informal caregivers.
Interventions Usual care provided by memory clinic or general
practitioner.
Main outcome measures Caregiver rated quality of life of the patient
measured with the quality of life in Alzheimer’s disease instrument and
self perceived burden of the informal caregiver measured with the sense
of competence questionnaire (intention to treat analysis).
Results The quality of life of the patients in the memory clinic group was
0.5 (95% confidence interval −0.7 to 1.6) points higher than in the general
practitioner group. Caregivers’ burden was 2.4 (−5.8 to 1.0) points lower
in the memory clinic group than in the general practitioner group.
Conclusion No evidence was found that memory clinics were more
effective than general practitioners with regard to post-diagnosis
treatment and coordination care for patients with dementia. Without
further evidence on the effectiveness of these modalities, other
arguments, such as cost minimisation, patients’ preferences, or regional
health service planning, can determine which type of dementia care is
offered.
Trial registration Clinical trials NCT00554047.
Introduction
Memoryclinicsusedtofocusondiagnosingdementia.However,
they are increasingly involved in post-diagnosis treatment and
coordination of care, especially since the introduction of
anti-dementia drugs (cholinesterase inhibitors) in the 1990s.
Previous research has indicated that memory clinics as
diagnosticfacilitiesareanefficienthealthcareinvestment,
1-4but
nodirectscientificevidenceshowstheeffectivenessoftreatment
and follow-up of dementia by memory clinics.
5 6
A few years ago, Great Britain announced a national dementia
strategy.
7 The main goals of the strategy are improving public
and professional awareness of dementia, enhancing early
diagnosis and intervention for everyone, and providing higher
quality care and support during all stages of dementia.
8 9 This
national strategy intends to achieve its goals by providing easy
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Research
RESEARCHaccesstoservicesandsupportthroughestablishinganationwide
network of multidisciplinary memory clinics. The
implementation of this strategy has led to a widespread
discussion on the justification of this approach.
6 10-14 The critics
of this strategy question the effectiveness of the treatment and
follow-up memory clinics provide after a diagnosis is made.
15
The discussion about the best way to treat and provide care for
patients with dementia is also a matter of debate in other
countries.
14 16 17 To our knowledge, no randomised trials
comparing the effectiveness of post-diagnosis dementia
treatment and care coordination by memory clinics and general
practitioners have been published. The PLASA study, which
was recently conducted in France, compared a comprehensive
specificcareplanwithusualdementiafollow-upcareinmemory
clinic settings.
18 Furthermore, few studies have evaluated the
effectiveness of memory clinics as a diagnostic setting. Wolfs
and colleagues showed that in comparison with the usual
diagnostic approach, an integrated multidisciplinary diagnostic
approach for dementia was effective.
4 Another study showed
some beneficial effects of diagnosis of dementia at a memory
clinic(asopposedtonotbeingofferedthisservice)onthehealth
related quality of life of caregivers.
19 However, the important
question of what is the best way to organise post-diagnosis
treatment and coordination of care for dementia remains
unanswered. We designed this study to determine the
effectivenessofpost-diagnosistreatmentandcarecoordination
for patients with dementia and their caregivers by memory
clinics compared with care provided by general practitioners.
Methods
Study design
This study (the AD-Euro Study), was a pragmatic multicentre
randomised trial with 12 months’ follow-up. Web based
randomisation took place after baseline measurements.
Participants (patient-caregiver pairs) were assigned for
post-diagnosis dementia care to either the memory clinic or the
generalpractitioner.Minimisationfactorsusedforrandomisation
were patient’s sex, caregiver’s sex, patient’s age, type of
dementia,severityofdementia,therelationshipbetweenpatient
and caregiver, and centre.
20 Details of the study design have
been published elsewhere.
21
Participants
From December 2007 until July 2009, nine Dutch memory
clinics recruited participants after diagnostic investigation.
Patientshadtobenewlydiagnosedashavingdementiameeting
the criteria of the Diagnostic and Statistical Manual of Mental
Disorders, fourth edition (DSM-IV), with a clinical dementia
rating of 0.5, 1, or 2.
22 Each patient had an informal caregiver,
and patient and informal caregiver both gave informed consent
before inclusion in the study. Patient-caregiver pairs were
excluded when the patient lived in a nursing home, had a life
expectancyoflessthanayear,orneededspecificmemoryclinic
care(forexample,inthecaseofCreutzfeldt-Jakobdisease)that
could not be given by general practitioners.
Intervention
The interventions in this study consisted of usual care by either
thememoryclinicorthegeneralpractitioner.Thememoryclinic
providedtreatmentandcarecoordinationbasedonthespecialist
Dutch dementia guideline of the Dutch Institute for Healthcare
Improvement.
23 The main content of the intervention of the
memory clinic was prescribing and guidance of anti-dementia
drugs (cholinesterase inhibitors and memantine). Furthermore,
they provided non-drug interventions—for example,
occupational therapy, providing day structure, or referral to a
nurse specialist, day care, or home care. Using the guidelines
mentioned, both drug prescription/guidance and the non-drug
interventions were delivered on a tailored basis.
Patient-caregiver pairs assigned to the general practitioner
received post-diagnosis treatment and care provided by the
general practitioner based on the Dutch general practice and
homecare dementia guidelines.
24 25 As usual, the general
practitioner received a discharge letter with advice about
treatment after diagnostic investigation by the memory clinic.
ContrarytotheDutchspecialistguidelineondementiatreatment,
thegeneralpracticeguidelinestatesthattheuseofcholinesterase
inhibitors is not recommended; however, several general
practitioners did prescribe dementia drugs as part of the
intervention.Mostnon-druginterventionsavailableinmemory
clinic care are also available in general practitioner care and
were also delivered on a tailored basis.
Measurements
After baseline measurements, follow-up measurements were
made at six and 12 months. Research assistants, who were
blinded to group allocation, made these measurements at the
patient’s home. At three and nine months, a short interview by
telephone was conducted with the informal caregiver. An
overview of the outcome measures and when they were used
has been published elsewhere.
21
Primary outcome measures
Primary outcome measures to establish effectiveness were the
quality of life of the patient as rated by the caregiver, using the
quality of life in Alzheimer’s disease instrument (range 13-52;
higher scores indicate a better quality of life),
26 and self
perceived caregiving burden of the informal caregiver, as
measured by the sense of competence questionnaire (range
27-135; higher score reflects a greater sense of competence).
27
Secondary outcome measures
Several secondary outcome measures in both patients and
caregivers were assessed. To measure patients’ depression, we
used the geriatric depression scale,
28 a short questionnaire
validated in mild to moderate dementia. We measured
behaviouraldisturbancebyusingtheneuropsychiatricinventory
inquestionnaireformatandthepatient’sfunctionalperformance
byusingtheinterviewfordeteriorationindailylivingactivities
in dementia scale.
29 30 Secondary outcome measures related to
the caregiver were mood measured with the Centre for
Epidemiologic Studies depression scale and anxiety measured
with the state-trait anxiety inventory.
31 32 We also used the
Eysenck personality questionnaire to evaluate caregivers’
personality and the Pearlin mastery scale to determine the
amount of mastery (the extent to which life chances are seen as
being under a person’s own control in contrast to being
fatalistically ruled).
33 34 We measured emotional problems of
the caregiver concerning the behaviour of the patient with the
neuropsychiatricinventoryinquestionnaireformat.
29Tomeasure
social support, we used the inventory for measuring social
involvement.
35
Statistical analysis
Weuseddescriptivestatisticstoanalysebaselinecharacteristics.
We analysed effectiveness in two linear regression models on
the quality of life in Alzheimer’s disease instrument and sense
of competence questionnaire, with the baseline value of the
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RESEARCHrespectiveoutcomemeasureandtheminimisationfactorsadded
to the model as covariates.
36 We used an intention to treat
analysis.
37 As a minimal clinically important difference, we
defined an average change in the quality of life in Alzheimer’s
disease instrument of 3 points on a scale ranging from 13 (very
poor quality of life) to 52 (very good quality of life) and used
a standard deviation of 6 in the sample size calculation. We
judged an improvement of 3 points on this instrument to be
clinically relevant, as this represents a change of wellbeing on
onedomainof qualityof life fromverypoor toexcellent.
26 This
change was also judged clinically relevant in an earlier
intervention trial in dementia.
26 38 For the sense of competence
questionnaire, we defined a minimal clinically important
difference as a 5 point change on a scale from 27 to 135 (higher
scorereflectsagreatersenseofcompetence)andusedastandard
deviation of 8 in the sample size calculation. An improvement
of 5 points was used in another trial on the effects of
occupational therapy in Alzheimer’s disease.
39
We regarded memory clinic care as superior to general
practitioner care when it was either superior on the quality of
life in Alzheimer’s disease instrument and non-inferior on the
sense of competence questionnaire (or vice versa) or superior
on both measures at 12 months’ follow-up. We set the lower
margin for non-inferiority at −1 for the quality of life in
Alzheimer’s disease instrument and at −1.5 for the sense of
competence questionnaire. We calculated the sample size to be
220 patients, accounting for a 30% attrition rate equally
distributed over both arms. With α=0.05 and an expected
treatmentdifferenceinfavourofmemorycliniccareof3points
on the quality of life in Alzheimer’s disease instrument and 5
pointsonthesenseofcompetencequestionnaire,thepowerwas
0.98 for showing superiority on at least one of the outcome
measures and non-inferiority on the other. The power was 0.84
for showing superiority on both outcome measures. We did not
replacemissingvalues,giventhattheattritionratewasmodest.
21
We did sensitivity analyses for the effect of missing data on the
results of the primary analyses by using the last observation
carriedforwardmethodandbyreplacingthemissingvaluewith
the mean of the other group.
40 We used Microsoft Office Excel
2007 and SPSS 16.0.01 (release 16.0.2) to do the statistical
analyses.
Results
We included 175 patient-caregiver pairs in the study; 87 were
randomly assigned to the memory clinic group and 88 to the
general practitioner group (figure⇓). Baseline characteristics of
patients and caregivers were similar between the two groups
(table 1⇓). Most of the patients (61%, n=106) and caregivers
(70%,n=123)werefemale.Theaverageageofthepatientswas
78.1(SD5.7)years,andcaregiverswereonaverage63.5(13.1)
years old. More than half of the caregivers (54%, n=94) were
partners, either married or living together with the patient, and
41% (n=72) of the caregivers were daughters or sons (or
daughters or sons in law). Most of the patients (60%, n=105)
had Alzheimer’s disease; in 84% (n=147) of the patients, the
severityofthedementiawasverymildtomild(clinicaldementia
rating 0.5 and 1). Cognition of the patients, measured with the
mini-mental state examination (range 0-30; higher score
indicates better cognition
41) at baseline was on average 22.7
(SD 3.9).
Of the 175 pairs included in the study, 22 pairs dropped out
duringthefollow-upperiod—13pairsinthegeneralpractitioner
groupandninepairsinthememoryclinicgroup(figure⇓).Four
patients (three in the memory clinic group) and two caregivers
(bothinthegeneralpractitionergroup)diedduringthefollow-up
phase. Eleven pairs (four in the memory clinic group) dropped
out because they considered further participation to be too
burdensome. Two caregivers (one in each group) contracted a
serious illness and dropped out. One caregiver in the memory
clinicgroupdidnotfilloutthequestionnaires,andonecaregiver
in the general practitioner group was not present during the
measurementswithoutgivinganyreasons.Finally,onediagnosis
of dementia in a patient in the general practitioner group was
changed just after inclusion.
Outcomes
Out of the 175 patient-caregiver pairs, 153 pairs (75 in the
general practitioner group and 78 in the memory clinic group)
were evaluated for the primary effectiveness outcomes (quality
of life in Alzheimer’s disease instrument and sense of
competencequestionnaire)at12months’follow-up.Thepatients
inthememoryclinicgroupscored0.5(95%confidenceinterval
−0.7 to 1.6) points higher on the quality of life in Alzheimer’s
disease instrument than did those in the general practitioner
group. Caregivers in the memory clinic group scored 2.4 (−5.8
to 1.0) points lower on the sense of competence questionnaire
thandidthoseinthegeneralpractitionergroup(table2⇓).None
ofthedifferenceswasstatisticallysignificant.Thiswasalsothe
case at six months’ follow-up (table 2⇓). The results of the
sensitivityanalysesfortheprimaryoutcomemeasuresreplacing
the missing values by using last observation carried forward
and with the mean of the other group were comparable to the
results presented here.
After 12 months of follow-up, we found no statistically
significantdifferencebetweentreatmentarmsforthesecondary
outcome measures of the patients (table 2⇓). Three secondary
outcomemeasuresofcaregiversshowedstatisticallysignificant
differences between the two study groups in favour of the
general practitioner group (table 2⇓). These were two scales of
the state-trait anxiety inventory, measuring anxiety in general
(anxiety trait) and anxiety at the moment of measuring (anxiety
state), and the Centre for Epidemiologic Studies depression
scale, which measured depressive symptoms of the caregiver.
Anxiety trait was 2.1 (0.24 to 4.03) points higher, anxiety state
was 2.4 (0.35 to 4.36) points higher, and depression was 2.1
(0.15 to 4.02) points higher for the memory clinic group
compared with the general practitioner group. However, the
average scores on these instruments for the two groups were
wellbelowthecut-offsforrelevantclinicalsymptomsofanxiety
or depression.
31 32 On the outcome measures state-trait anxiety
inventory and Centre for Epidemiologic Studies depression
scale, we found differences in baseline scores between
participants who completed the study and those who dropped
out. Also, differences existed between the two study arms:
dropoutsinthegeneralpractitionerarmhadworsemeanbaseline
valuesforanxietytrait,anxietystate,anddepression(41.9,44.2,
and11.7),thandiddropoutsinthememoryclinicarm,whohad
values of 35.5, 35.2, and 9.3 (P<0.05). Baseline and 12 month
follow-up scores on each of these instruments were highly
correlated, with correlation coefficients of 0.79, 0.69, and 0.64.
Tobetterunderstandhowthesedifferencesmayhaveinfluenced
thesecondaryoutcomeresults,wedidtheanalysisofcovariance
againwithlastobservationcarriedforwardforthedropouts.On
both the state-trait anxiety inventory and the Centre for
EpidemiologicStudiesdepressionscale,thedifferencesbetween
thetwostudygroupsgotsmallerandloststatisticalsignificance.
At six months’ follow-up, two secondary outcome measures of
the caregiver, anxiety state and inventory for measuring social
involvement,showedsignificantdifferencesbetweenthegroups
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RESEARCHin favour of the general practitioners group (table 2⇓). Again,
participants who dropped out in the general practitioner group
at six months’ follow-up had a worse mean baseline value for
anxietystatethandiddropoutsinthememoryclinicgroup(43.8
v 37.5). We found no difference in the mean baseline value
betweencompletersanddropoutsontheinventoryformeasuring
social involvement.
Discussion
We found no evidence of a difference in effectiveness between
memory clinics and general practitioners with regard to
post-diagnosis treatment and coordination of care for patients
with dementia. The analysis suggests that being guided by a
general practitioner had a small positive effect on anxiety or
mood of the caregiver (secondary outcome measures), but this
may be the effect of selective loss to follow-up.
Comparison with other studies
Comparison of our results with others is difficult, because of
the lack of similar studies. The PLASA study looked at
effectivenessofaspecificcareplanprovidedbymemoryclinics
comparedwithregularcareprovidedbymemoryclinics.
18They
sawnoadditionalpositiveeffectonfunctionaldeclineinpatients
withAlzheimer’sdisease.Althoughtheprimaryoutcomeinthe
PLASA study was functional decline, this lack of additional
effect seems to correspond with our results. The study of Wolfs
et al showed that, in comparison with usual care, an integrated
multidisciplinarydiagnosticapproachtodementiainamemory
clinic setting increased the health related quality of life of
dementia patients and was cost effective.
3 Compared with our
study, their patients’ cognition was worse and the patients had
a much lower mean quality adjusted life year value, indicating
that our study included a population with better cognition and
betterqualityoflife.Furthermore,asimpleassociationmaynot
exist between outcomes relevant to patients such as health
related quality of life and discrete areas of function such as
cognition and behaviour. Moreover, the responsiveness of
outcome measures relevant to patients may be debated,
specificallyindementiapatients.
42Therefore,nexttotheprimary
outcome measure, the quality of life in Alzheimer’s disease
instrument, we also evaluated the two types of care for their
effectsonclinicallyrelevantoutcomemeasuressuchasfunction,
cognition, and behaviour, but we were unable to show
superiorityformemorycliniccareonthesemeasures.Moreover,
because of the importance of the burden on caregivers, we used
the sense of competence questionnaire as a primary outcome
measure.Thisturnedouttobehighlyresponsiveinarandomised
controlled trial of occupational therapy in the same population
ofdementiapatients.
39Wefoundnoindicationsforadifference
between the memory clinic and general practitioner groups on
the sense of competence questionnaire.
Strengths and limitations
By using a randomised clinical trial, we ensured a robust study
design.Theparticipationofninedifferentmemoryclinics,based
in different settings (university hospital, general hospital, old
age psychiatry), enhanced the generalisability of our study.
However, we recruited participants only from memory clinics
and not from general practices, which means that the results
may notberepresentative for all patientswithmildtomoderate
dementia in the general population, although a considerable
proportion (27%) of all cases of dementia are diagnosed at a
memoryclinicintheNetherlands.
43Recruitingpatientsthrough
thememoryclinicsensuredathoroughandconsistentdiagnosis.
On the other hand, differences in healthcare systems between
countries make generalisability more difficult. Variability in
dementia care exists within the Netherlands as well as between
different countries, possibly owing to the rapid increase in the
numberofmemoryclinicsrecentlyandthemanydevelopments
in dementia care. However, quality indicators for both general
practitioners and memory clinics are now being implemented
in different European countries, which will hopefully improve
comparability of dementia care in the future.
44-46
Two other limitations could have affected the outcomes of this
study. Dementia is a disease that progresses over years, so an
extended follow-up lasting several years would be preferable
to the relatively short 12 month period we used. In addition, the
type of intervention under study did not allow us to use double
blindprocedures.However,asourstudywasapragmatictrial,
21
biases as a result of not using double blind procedures are
generally not viewed as detrimental but accepted as part of
physicians’ and patients’ responses to treatment and included
in the overall assessment.
47 In pragmatic approaches, the
treatment response is the total difference between two
treatments, which includes both treatment and placebo effects,
asthiswillbestreflectthelikelyclinicalresponseinpractice.
47 48
Implications and conclusions
With the results of our study, we provide empirical data on
differencesineffectivenessbetweenmemoryclinicsandgeneral
practitioners. These data can now fuel the ongoing debate on
which type of post-diagnosis treatment and follow-up is best
for which patients. The debate that followed the appearance of
the UK national dementia strategy (NDS), has once more
stressed the need to continue to compare different strategies of
dementia care and to continue to increase the evidence base:
“NDS is not a beginning but a point in time in the progressive
improvement of services for people with dementia and their
families. . . Strengthening the potential of primary care and
including it in collaborative systems will be the best way to use
our new knowledge.”
15
The AD-Euro study adds important data, which seem to point
to a lack of difference in effectiveness between memory clinics
and general practitioners in the treatment and coordination of
care for patients with dementia. Other factors can and should
thus determine the preference for one provider over the
other—for example, patients’ and caregivers’ preferences or
regional or national planning to concentrate specific services.
Cost minimisation may also be a strong argument if quality of
care can be shown to be guaranteed. Further empirical data are
needed before we will be able to press this point. A different
and potentially very promising direction would be to start to
integrate the resources of memory clinics and general
practitioners and to combine their knowledge and experience
tobuildtrulyintegrateddementiacarethatmayoptimallyserve
the increasing number of patients with dementia in the future.
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RESEARCHWhat is already known on this topic
The number of memory clinics has increased rapidly over the past decades
Memory clinics have been shown to be effective as diagnostic facilities
What this study adds
No evidence was found of a difference in effectiveness between memory clinics and general practitioners in treating and coordinating
care for patients with dementia
Patients’ and caregivers’ preferences, cost minimisation, or a policy of concentrating specific services may determine the preference
for memory clinic or general practitioner for post-diagnosis care
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RESEARCHTables
Table 1| Baseline characteristics of participants in memory clinic (MC) group and general practitioner (GP) group. Values are numbers
(percentages) unless stated otherwise
GP group (n=88) MC group (n=87)
Characteristics Caregiver Patient Caregiver Patient
61 (69) 52 (59) 62 (71) 54 (62) Female
63.9 (12.9) 77.9 (5.2) 63.2 (13.4) 78.2 (6.2) Mean (SD) age (years)
Type of dementia:
– 52 (59) – 53 (61) Alzheimer’s disease
– 6 (7) – 9 (10) Vascular dementia
– 30 (34) – 25 (29) Mixed/other
Severity of dementia:
– 5 (6) – 3 (3) CDR 0.5
– 69 (78) – 70 (80) CDR 1
– 14 (16) – 14 (16) CDR 2
Relationship with caregiver:
– 48 (55) – 46 (53) Partner
– 36 (41) – 36 (41) Child (in law)
– 4 (5) – 5 (6) Other
Education,:
7 (8) 30 (34) 10 (11) 31 (36) Low
56 (64) 36 (41) 52 (60) 35 (40) Middle
24 (27) 21 (24) 25 (29) 20 (23) High
Mean (SD) scores:
105.1 (13.7) – 107.9 (15.0) – SCQ
– 30.7 (4.7) – 30.6 (5.2) QoL-AD patient, as rated by
caregiver
– 8.8 (4.6) – 9.2 (4.4) CIRS G
– 22.7 (4.2) – 22.7 (3.6) MMSE
– 2.6 (2.3) – 2.6 (2.5) GDS
– 13.4 (9.1) – 13.8 (8.8) IDDD help needed
– 12.3 (6.8) – 13.2 (7.7) IDDD take initiative
– 7.7 (6.2) – 7.1 (6.1) NPI behaviour
38.5 (4.7) 36.2 (4.4) 37.6 (3.6) 36.1 (4.2) QoL-AD
9.8 (7.6) – 9.3 (7.6) – CES D
10.3 (8.8) – 9.1 (9.4) – NPI emotional
34.6 (9.1) – 34.0 (10.2) – STAI trait
36.5 (9.3) – 34.9 (9.7) – STAI state
3.0 (2.9) – 2.6 (3.2) – EPQ
16.7 (4.7) – 16.5 (4.0) – PMS
12.3 (3.2) – 12.2 (3.0) – ISB
CDR=clinical dementia rating scale (range 0-3; higher score indicates more severe dementia); CES D=Center for Epidemiologic Studies depression scale (range
0-60; higher score indicates more depressive); CIRS G=cumulative illness rating scale for geriatrics (range 0-56; higher score indicates more comorbidity);
EPQ=Eysenck personality questionnaire, short version, neuroticism (range 0-12; higher score indicates more worried); GDS=geriatric depression scale (range
0-15; higher score indicates more depressive); IDDD=interview for deterioration in daily living activities in dementia (range for “help needed” 0-44; range for “take
initiative” 0-36; higher score indicates more help needed or less initiative taken); ISB=inventory for measuring social involvement (range 4-16; higher score indicates
more social support); MMSE=mini-mental state examination (range 0-30; higher score indicates better cognition); NPI behaviour=neuropsychiatric inventory in
questionnaire format (range 0-36; higher score indicates more behavioural disturbance); NPI emotional= neuropsychiatric inventory in questionnaire format; range
0-60; higher score indicates more emotional problems); PMS=Pearlin mastery scale (range 7-35; higher score indicates less own control; QoL-AD=quality of life
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RESEARCHTable 1 (continued)
GP group (n=88) MC group (n=87)
Characteristics Caregiver Patient Caregiver Patient
in Alzheimer’s disease (range 13-52; higher score indicates better quality of life); SCQ=sense of competence questionnaire (range 27-135; higher score reflects
greater sense of competence); STAI=state-trait anxiety inventory (range 20-80; higher score indicates more anxiety.
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RESEARCHTable 2| Analysis of covariance for difference between memory clinic (MC) and general practitioner (GP) groups for primary and secondary
outcome measures at 6 and 12 months’ follow-up
12 months’ follow-up 6 months’ follow-up
No P value
Difference (95% CI)
between MC and GP* No P value
Difference (95% CI)
between MC and GP*
Patients’ outcomes
153 0.40 0.49 (−0.66 to 1.63) 153 0.32 0.58 (−0.57 to 1.73) QoL-AD patient, as
rated by caregiver†
152 0.18 1.13 (−0.51 to 2.77) 154 0.39 0.63 (−0.81 to 2.06) NPI behaviour
148 0.61 0.66 (−1.88 to 3.20) 151 0.28 1.30 (−1.08 to 3.69) IDDD help needed
152 0.08 1.69 (−0.18 to 3.56) 153 0.64 0.44 (−1.38 to 2.26) IDDD take initiative
139 0.41 0.25 (−0.36 to 0.86) 150 0.91 −0.03 (−0.56 to 0.50) GDS
145 0.62 0.25 (−0.76 to 1.23) 153 0.68 0.19 (−0.74 to 1.13) QoL-AD patient
Caregivers’ outcomes
153 0.16 −2.43 (−5.82 to 0.96) 156 0.52 −0.93 (−3.75 to 1.89) SCQ†
154 0.70 0.17 (−0.70 to 1.04) 154 0.64 −0.20 (−1.07 to 0.66) QoL-AD caregiver
151 0.04 2.09 (0.15 to 4.02) 153 0.96 0.05 (−2.04 to 2.13) CES D
151 0.39 −0.29 (−0.97 to 0.78) 154 0.02 −0.84 (−1.54 to −0.14) ISB
152 0.24 1.43 (−0.94 to 3.80) 153 0.22 1.29 (−0.77 to 3.35) NPI emotional
151 0.05 0.68 (−0.01 to 1.36) – – – EPQ‡
152 0.03 2.14 (0.24 to 4.03) – – – STAI trait‡
151 0.02 2.35 (0.35 to 4.36) 151 0.002 3.55 (1.29 to 5.81) STAI state
152 0.27 0.65 (−0.51 to 1.80) 152 0.95 −0.03 (−1.17 to 1.10) PMS
CES D=Center for Epidemiologic Studies depression scale (range 0-60; higher score indicates more depressive); CIRS G=cumulative illness rating scale for
geriatrics (range 0-56; higher score indicates more comorbidity); EPQ=Eysenck personality questionnaire, short version, neuroticism (range 0-12; higher score
indicates more worried; GDS=geriatric depression scale (range 0-15; higher score indicates more depressive); IDDD=interview for deterioration in daily living
activities in dementia (range for “help needed” 0-44; range for “take initiative” 0-36; higher score indicates more help needed or less initiative taken); ISB=inventory
for measuring social involvement (range 4-16; higher score indicates more social support); MMSE=mini-mental state examination (range 0-30; higher score
indicates better cognition); NPI behaviour=neuropsychiatric inventory in questionnaire format (range 0-36; higher score indicates more behavioural disturbance);
NPI emotional= neuropsychiatric inventory in questionnaire format; range 0-60; higher score indicates more emotional problems); PMS=Pearlin mastery scale
(range 7-35; higher score indicates less own control; QoL-AD=quality of life in Alzheimer’s disease (range 13-52; higher score indicates better quality of life);
SCQ=sense of competence questionnaire (range 27-135; higher score reflects greater sense of competence); STAI=state-trait anxiety inventory (range 20-80;
higher score indicates more anxiety.
*Adjusted for type of dementia, severity of dementia, patient’s sex, patient’s age, caregiver’s sex, relationship of patient to caregiver, memory clinic involved, and
baseline measurement of relevant outcome.
†Primary outcome measures.
‡Not measured at 6 months’ follow-up.
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Flow diagram of study
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